Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors

Nivya James1, V Shanthi1, K Ramanathan2

  • 1Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.

Insights

Researchers identified novel anaplastic lymphoma kinase (ALK) inhibitors for non-small cell lung cancer (NSCLC) treatment. Computational methods screened databases, yielding two promising compounds with favorable ADMET properties and high ALK affinity.

Area of Science:

  • Computational chemistry
  • Drug discovery
  • Oncology

Background:

  • Targeting anaplastic lymphoma kinase (ALK) is a key strategy in non-small cell lung cancer (NSCLC) therapy.
  • Developing novel ALK inhibitors requires advanced computational screening and validation methods.

Purpose of the Study:

  • To identify novel ALK inhibitors using a multidimensional computational approach.
  • To evaluate the potential efficacy and safety of identified compounds for NSCLC treatment.

Main Methods:

  • Generation of an e-pharmacophore model and screening of the ASINEX database.
  • Hierarchical docking, binding free energy calculations, and ADMET property prediction.
  • Density functional theory and molecular dynamics simulations for validation.

Main Results:

  • Two lead compounds, BAS 00137817 and BAS 00680055, were identified with high affinity for ALK.
  • These compounds demonstrated acceptable absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles.
  • Identified scaffolds are crucial for downregulating ALK-positive lung cancer pathways.

Conclusions:

  • The study successfully identified novel ALK inhibitors with potential for NSCLC treatment.
  • The findings support the rational design of new, effective ALK inhibitors.
  • Computational approaches are valuable for accelerating drug discovery in oncology.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K